查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985844

病毒載體和質體DNA生產市場規模、佔有率和趨勢分析報告：按載體類型、工作流程、應用、最終用途、疾病、地區和細分市場預測，2026-2033年

Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type, By Workflow, By Application, By End-use, By Disease, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

病毒載體與質體DNA生產市場概述

全球病毒載體和質體DNA生產市場預計在2025年達到66.8億美元，預計到2033年將達到195.2億美元，2026年至2033年的複合年成長率為14.5%。

市場的主要驅動力之一是基因療法的進步，因為新基因治療方法的開發很大程度上依賴高品質的病毒載體和質體DNA。

此外，製造流程的改進使得病毒載體和質體DNA的生產規模更大、效率更高，同時也降低了成本並提高了整體品質。病毒載體和質體DNA生產市場的成長主要受基因治療和細胞治療需求不斷成長的推動，尤其是在北美和歐洲。美國質體DNA生產市場佔據領先地位，這得益於活躍的臨床試驗活動、CDMO公司的強大實力以及質體DNA契約製造市場外包趨勢的日益成長。同時，在政府主導的生命科學舉措和先進的研究基礎設施的支持下，英國病毒載體和質體DNA生產市場也持續擴張。在各個地區，病毒載體和質體DNA生產市場以及質體DNA生產市場都受益於生物技術投資的增加、製造商產能的提升以及對可擴展的、符合GMP規範的生產系統日益成長的需求，這些系統旨在支持研發、臨床開發和商業化。

細胞和基因療法的快速發展，尤其是在腫瘤、罕見疾病和遺傳性疾病領域，以及臨床試驗數量的不斷增加和CAR-T、AAV基因療法和mRNA平台等先進治療方法監管核准的日益增多，顯著提升了對高品質病毒載體和質體DNA的需求。隨著生物製藥公司將專案從早期研究推進到後期開發和商業化階段，對可擴展的、符合GMP規範的生產能力的需求也在持續成長。

此外，對學術研究、生物技術創新和個人化醫療的持續投入進一步推動了市場成長。研究機構和新興生技公司越來越依賴外包合作夥伴進行生產，以克服技術複雜性、高昂的資本成本和嚴格的監管要求。 CDMO（合約研發生產機構）產能的擴張、載體生產技術的進步以及政府對生命科學基礎設施日益成長的支持，都促使全球對可靠高效的病毒載體和質體DNA生產解決方案的需求不斷成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：病毒載體和質體DNA生產市場的因素、趨勢和範圍

  • 市場歷史及展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 病毒載體和質體DNA生產市場的分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析

第4章：病毒載體與質體DNA生產市場：依載體類型分類的估算與趨勢分析

  • 全球病毒載體與質體DNA生產市場：按載體類型分類的展望
  • 腺結合病毒（AAV）
  • 慢病毒
  • 腺病毒
  • 逆轉錄病毒
  • 質體
  • 其他

第5章：病毒載體與質體DNA生產市場：依工作流程分類的估算與趨勢分析

  • 全球病毒載體與質體DNA生產市場：依工作流程分類的展望
  • 上游製造
    • 向量放大/增大
    • 病媒回收/收集
  • 下游製造
    • 純化
    • 填充完成診斷設備

第6章：病毒載體與質體DNA生產市場：依應用分類的估算與趨勢分析

  • 全球病毒載體與質體DNA生產市場：按應用領域分類的展望
  • 反義RNA干擾
  • 基因治療
  • 細胞療法
  • 疫苗
  • 研究與應用

第7章：病毒載體與質體DNA生產市場：依最終用途分類的估算與趨勢分析

  • 全球病毒載體與質體DNA生產市場：依最終用途分類的展望
  • 製藥和生物製藥公司
  • 研究機構

第8章：病毒載體和質體DNA生產市場：疾病特異性估算和趨勢分析

  • 全球病毒載體與質體DNA生產市場：疾病特異性展望
  • 癌症
  • 遺傳性疾病
  • 感染疾病
  • 其他

第9章：病毒載體和質體DNA生產市場：區域估算和趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 公司分類
  • 策略規劃
  • 2025年企業市場分析
  • 公司簡介/列表
    • Merck KGaA
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Thermo Fisher Scientific
    • Cobra Biologics
    • Catalent Inc.
    • Wuxi Biologics
    • Takara Bio Inc.
    • Waisman Biomanufacturing
    • Genezen laboratories
    • Batavia Biosciences
    • Miltenyi Biotec GmbH
    • SIRION Biotech GmbH
    • Virovek Incorporation
    • BioNTech IMFS GmbH
    • Audentes Therapeutics
    • BioMarin Pharmaceutical
    • RegenxBio, Inc.
Product Code: GVR-2-68038-695-0

Viral Vectors And Plasmid DNA Manufacturing Market Summary

The global viral vector and plasmid DNA manufacturing market size was estimated at USD 6.68 billion in 2025 and is projected to reach USD 19.52 billion by 2033, growing at a CAGR of 14.5% from 2026 to 2033. One of the primary factors driving the market is the advancement in gene therapy, as the development of new gene therapies is heavily reliant on high-quality viral vectors and plasmid DNA.

Furthermore, improvements in manufacturing processes have made it possible to produce viral vectors and plasmid DNA more efficiently at larger scales, while also reducing costs and improving overall quality. The growth of the viral vectors and plasmid DNA manufacturing market has been strongly driven by rising demand for gene and cell therapies, particularly across North America and Europe. The U.S. plasmid DNA manufacturing market leads due to high clinical trial activity, strong CDMO presence, and increasing outsourcing trends within the plasmid DNA contract manufacturing market. Meanwhile, the UK viral vectors plasmid DNA manufacturing market continues to expand, supported by government-backed life sciences initiatives and advanced research infrastructure. Across regions, the broader viral vector and plasmid DNA manufacturing market and the DNA plasmid manufacturing market are benefiting from growing biotech investments, capacity expansion by manufacturers, and the need for scalable, GMP-compliant production to support research, clinical development, and commercialization.

The rapid growth of cell and gene therapies, particularly in oncology, rare diseases, and genetic disorders. Increasing numbers of clinical trials, along with rising regulatory approvals for advanced therapies such as CAR-T, AAV-based gene therapies, and mRNA platforms, have significantly boosted demand for high-quality viral vectors and plasmid DNA. As biopharmaceutical companies move programs from early research into late-stage development and commercialization, the need for scalable, GMP-compliant manufacturing capabilities has continued to expand.

In addition, sustained investments in academic research, biotechnology innovation, and personalized medicine have further supported market growth. Research institutes and emerging biotech companies increasingly rely on outsourced manufacturing partners to overcome technical complexity, high capital costs, and stringent regulatory requirements. Capacity expansions by CDMOs, advancements in vector production technologies, and growing government support for life sciences infrastructure have collectively strengthened demand for reliable and efficient viral vector and plasmid DNA manufacturing solutions worldwide.

Global Viral Vector And Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global viral vector and plasmid DNA manufacturing market report based on vector type, workflow, application, end-use, disease, and region.

  • Vector Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Adeno-associated virus (AAV)
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Plasmids
  • Others
  • Workflow Outlook (Revenue, USD Billion, 2021 - 2033)
  • Upstream Manufacturing
    • Vector Amplification & Expansion
    • Vector Recovery/Harvesting
  • Downstream Manufacturing
    • Purification
    • Fill Finish
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications
  • End-use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Disease Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • Kuwait
    • UAE
    • South Africa
    • Saudi Arabia

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vector type
    • 1.2.2. Workflow
    • 1.2.3. Application
    • 1.2.4. End Use
    • 1.2.5. Disease
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
      • 3.2.1.2. Technological Advancements in Manufacturing Vectors
      • 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
  • 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
  • 4.3. Adeno-associated Virus (AAV)
    • 4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4. Lentivirus
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Adenovirus
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Retrovirus
    • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Plasmids
    • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
  • 5.3. Upstream Manufacturing
    • 5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Vector Amplification & Expansion
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3. Vector Recovery/Harvesting
      • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4. Downstream Manufacturing
    • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Purification
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Fill Finish diagnostic instruments
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
  • 6.3. Antisense & RNAi
    • 6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4. Gene Therapy
    • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Cell Therapy
    • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Vaccinology
    • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Research Applications
    • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by End Use Outlook
  • 7.3. Pharmaceutical and Biopharmaceutical Companies
    • 7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Research Institutes
    • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
  • 8.3. Cancer
    • 8.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4. Genetic Disorders
    • 8.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Other
    • 8.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2025 & 2033
  • 9.2. North America
    • 9.2.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key country dynamics
      • 9.2.2.2. Regulatory framework
      • 9.2.2.3. Competitive scenario
      • 9.2.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Key country dynamics
      • 9.2.3.2. Regulatory framework
      • 9.2.3.3. Competitive scenario
      • 9.2.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Key country dynamics
      • 9.2.4.2. Regulatory framework
      • 9.2.4.3. Competitive scenario
      • 9.2.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. Key country dynamics
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive scenario
      • 9.3.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Key country dynamics
      • 9.3.5.2. Regulatory framework
      • 9.3.5.3. Competitive scenario
      • 9.3.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Key country dynamics
      • 9.3.6.2. Regulatory framework
      • 9.3.6.3. Competitive scenario
      • 9.3.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.7. Norway
      • 9.3.7.1. Key country dynamics
      • 9.3.7.2. Regulatory framework
      • 9.3.7.3. Competitive scenario
      • 9.3.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Key country dynamics
      • 9.3.8.2. Regulatory framework
      • 9.3.8.3. Competitive scenario
      • 9.3.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.9. Denmark
      • 9.3.9.1. Key country dynamics
      • 9.3.9.2. Regulatory framework
      • 9.3.9.3. Competitive scenario
      • 9.3.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.3. China
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.5. Australia
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.6. South Korea
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6. MEA
    • 9.6.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Position Analysis, 2025
  • 10.4. Company Profiles/Listing
    • 10.4.1. Merck KGaA
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Lonza
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. FUJIFILM Diosynth Biotechnologies
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Thermo Fisher Scientific
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Cobra Biologics
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. Catalent Inc.
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. Wuxi Biologics
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives
    • 10.4.8. Takara Bio Inc.
      • 10.4.8.1. Company overview
      • 10.4.8.2. Financial performance
      • 10.4.8.3. Product benchmarking
      • 10.4.8.4. Strategic initiatives
    • 10.4.9. Waisman Biomanufacturing
      • 10.4.9.1. Company overview
      • 10.4.9.2. Financial performance
      • 10.4.9.3. Product benchmarking
      • 10.4.9.4. Strategic initiatives
    • 10.4.10. Genezen laboratories
      • 10.4.10.1. Company overview
      • 10.4.10.2. Financial performance
      • 10.4.10.3. Product benchmarking
      • 10.4.10.4. Strategic initiatives
    • 10.4.11. Batavia Biosciences
      • 10.4.11.1. Company overview
      • 10.4.11.2. Financial performance
      • 10.4.11.3. Product benchmarking
      • 10.4.11.4. Strategic initiatives
    • 10.4.12. Miltenyi Biotec GmbH
      • 10.4.12.1. Company overview
      • 10.4.12.2. Financial performance
      • 10.4.12.3. Product benchmarking
      • 10.4.12.4. Strategic initiatives
    • 10.4.13. SIRION Biotech GmbH
      • 10.4.13.1. Company overview
      • 10.4.13.2. Financial performance
      • 10.4.13.3. Product benchmarking
      • 10.4.13.4. Strategic initiatives
    • 10.4.14. Virovek Incorporation
      • 10.4.14.1. Company overview
      • 10.4.14.2. Financial performance
      • 10.4.14.3. Product benchmarking
      • 10.4.14.4. Strategic initiatives
    • 10.4.15. BioNTech IMFS GmbH
      • 10.4.15.1. Company overview
      • 10.4.15.2. Financial performance
      • 10.4.15.3. Product benchmarking
      • 10.4.15.4. Strategic initiatives
    • 10.4.16. Audentes Therapeutics
      • 10.4.16.1. Company overview
      • 10.4.16.2. Financial performance
      • 10.4.16.3. Product benchmarking
      • 10.4.16.4. Strategic initiatives
    • 10.4.17. BioMarin Pharmaceutical
      • 10.4.17.1. Company overview
      • 10.4.17.2. Financial performance
      • 10.4.17.3. Product benchmarking
      • 10.4.17.4. Strategic initiatives
    • 10.4.18. RegenxBio, Inc.
      • 10.4.18.1. Company overview
      • 10.4.18.2. Financial performance
      • 10.4.18.3. Product benchmarking
      • 10.4.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 18 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 19 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 20 Mexico viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 21 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 22 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 23 Europe viral vector and plasmid DNA manufacturing market, by region, 2021 - 2033 (USD Million)
  • Table 24 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 25 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 26 Europe viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 27 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 28 Europe viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 29 UK viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 30 UK viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 31 UK viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 32 UK viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 33 UK viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 34 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 35 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 36 Germany viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 37 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 38 Germany viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 39 France viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 40 France viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 41 France viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 42 France viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 43 France viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 44 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 45 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 46 Spain viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 47 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 48 Spain viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 49 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 50 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 51 Italy viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 52 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 53 Italy viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 54 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 55 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 56 Denmark viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 57 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 58 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 59 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 60 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 61 Sweden viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 62 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 63 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 64 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 65 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 66 Norway viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 67 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 68 Norway viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 69 Asia Pacific viral vector and plasmid DNA manufacturing market, by region, 2021 - 2033 (USD Million)
  • Table 70 Asia Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 71 Asia Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 72 Asia Pacific viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 73 Asia Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 74 Asia Pacific viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 75 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 76 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 77 Japan viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 78 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 79 Japan viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 80 China viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 81 China viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 82 China viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 83 China viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 84 China viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 85 India viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 86 India viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 87 India viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 88 India viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 89 India viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 90 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 91 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 92 South Korea viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 93 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 94 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 95 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 96 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 97 Australia viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 98 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 99 Australia viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 100 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 101 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 102 Thailand viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 103 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 104 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 105 Latin America viral vector and plasmid DNA manufacturing market, by region, 2021 - 2033 (USD Million)
  • Table 106 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 107 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 108 Latin America viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 109 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 110 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 111 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 112 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 113 Brazil viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 114 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 115 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2021 - 2033 (USD Million)
  • Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)
  • Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2021 - 2033 (USD Million)
  • Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2021 - 2033 (USD Million)
  • Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2021 - 2033 (USD Million)
  • Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2021 - 2033 (USD Million)
  • Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
  • Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Viral vector and plasmid DNA manufacturing market driver impact
  • Fig. 14 Viral vector and plasmid DNA manufacturing market restraint impact
  • Fig. 15 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
  • Fig. 16 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
  • Fig. 17 Adenovirus market estimates and forecast, 2021 - 2033
  • Fig. 18 Retrovirus market estimates and forecast, 2021 - 2033
  • Fig. 19 Adeno-associated virus (AAV)market estimates and forecast, 2021 - 2033
  • Fig. 20 Lentivirus market estimates and forecast, 2021 - 2033
  • Fig. 21 Plasmids market estimates and forecast, 2021 - 2033
  • Fig. 22 Others market estimates and forecast, 2021 - 2033
  • Fig. 23 Viral vector and plasmid DNA manufacturing market: Workflow movement analysis
  • Fig. 24 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
  • Fig. 25 Upstream manufacturing market estimates and forecasts, 2021 - 2033
  • Fig. 26 Vector amplification & expansion market estimates and forecasts, 2021 - 2033
  • Fig. 27 Vector recovery/harvesting market estimates and forecasts, 2021 - 2033
  • Fig. 28 Downstream manufacturing market estimates and forecasts, 2021 - 2033
  • Fig. 29 Purification market estimates and forecasts, 2021 - 2033
  • Fig. 30 Fill finish market estimates and forecasts, 2021 - 2033
  • Fig. 31 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
  • Fig. 32 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
  • Fig. 33 Antisense & RNAi therapy market estimates and forecasts, 2021 - 2033
  • Fig. 34 Gene therapy market estimates and forecasts, 2021 - 2033
  • Fig. 35 Cell therapy market estimates and forecasts, 2021 - 2033
  • Fig. 36 Vaccinology market estimates and forecasts, 2021 - 2033
  • Fig. 37 Research applications market estimates and forecasts, 2021 - 2033
  • Fig. 38 Viral vector and plasmid DNA manufacturing market: End Use movement Analysis
  • Fig. 39 Viral vector and plasmid DNA manufacturing market: End Use outlook and key takeaways
  • Fig. 40 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2021 - 2033
  • Fig. 41 Research institutes market estimates and forecasts, 2021 - 2033
  • Fig. 42 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
  • Fig. 43 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
  • Fig. 44 Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 45 Genetic disorders market estimates and forecasts, 2021 - 2033
  • Fig. 46 Infectious diseases market estimates and forecasts, 2021 - 2033
  • Fig. 47 Others market estimates and forecasts, 2021 - 2033
  • Fig. 48 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
  • Fig. 49 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
  • Fig. 50 North America
  • Fig. 51 North America market estimates and forecasts, 2021 - 2033
  • Fig. 52 U.S.
  • Fig. 53 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 54 Canada
  • Fig. 55 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 56 Mexico
  • Fig. 57 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 58 Europe
  • Fig. 59 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 60 UK
  • Fig. 61 UK market estimates and forecasts, 2021 - 2033
  • Fig. 62 Germany
  • Fig. 63 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 64 France
  • Fig. 65 France market estimates and forecasts, 2021 - 2033
  • Fig. 66 Italy
  • Fig. 67 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 68 Spain
  • Fig. 69 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 70 Denmark
  • Fig. 71 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 72 Sweden
  • Fig. 73 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 74 Norway
  • Fig. 75 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 76 Asia Pacific
  • Fig. 77 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 78 China
  • Fig. 79 China market estimates and forecasts, 2021 - 2033
  • Fig. 80 Japan
  • Fig. 81 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 82 India
  • Fig. 83 India market estimates and forecasts, 2021 - 2033
  • Fig. 84 Thailand
  • Fig. 85 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 86 South Korea
  • Fig. 87 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 88 Australia
  • Fig. 89 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 90 Latin America
  • Fig. 91 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 92 Brazil
  • Fig. 93 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 94 Argentina
  • Fig. 95 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 96 Middle East and Africa
  • Fig. 97 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 98 South Africa
  • Fig. 99 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 100 Saudi Arabia
  • Fig. 101 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 102 UAE
  • Fig. 103 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 104 Kuwait
  • Fig. 105 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 106 Market share of key market players- Viral vector and plasmid DNA manufacturing market